Supplemental Online Content

Mousavi I, Olivier T, Prasad V. Cost per event averted in cancer trials in the adjuvant setting from 2018 to 2022. *JAMA Netw Open*. 2022;5(6):e2216058. doi:10.1001/jamanetworkopen.2022.16058

**eAppendix.** Cost per Event Averted Example Calculation

This supplemental material has been provided by the authors to give readers additional information about their work.
eAppendix: Cost Per Event Averted Example Calculation

- Example Calculation for Cost per Event Averted:
  - IMpower10 Trial - 3 yr (36 month) DFS endpoint (Intention-to-Treat population)
    - NNT = 1/ARR
      - % of ITT population in experimental group = 57.9%
      - % of ITT population in control group = 52.6%
    - NNT = 18.9
      - \(1/(ER_{\text{treatment}} - ER_{\text{control}})\) = NNT
    - Median treatment duration = 10.4 months
    - Monthly cost of atezolizumab = $11,363.82
    - Cost per patient = (11,363.82*10.4) = $118,183.728
  - Cost per event averted = NNT*cost per patient = 18.9*118,183.728 = $2,233,672.4592 (rounded = $2,230,000).